Crohn's Disease

Antibiotic exposure was associated with an increased and cumulative risk for inflammatory bowel disease and was highest among individuals aged 40 years and older, according to results from a Danish study published in Gut.

Ferric carboxymaltose induced a higher rate of hypophosphatemia compared with ferric derisomaltose among patients with inflammatory bowel disease-associated iron deficiency anemia, according to results published in Gut.

Topline findings from the phase 2 ARTEMIS-UC and phase 2a APOLLO-CD trials showed that PRA023, an anti-TL1A monoclonal antibody, was safe and effective for Crohn’s disease and ulcerative colitis, Prometheus Biosciences announced.

Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists.

CHARLOTTE, N.C. — Subcutaneous risankizumab as maintenance therapy was efficacious and well-tolerated in patients with Crohn’s disease who had a delayed response to induction, according to research at the ACG Annual Scientific Meeting.

After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s disease achieved remission, according to recent data.

In this edition, endoscopic hemostasis system cleared by FDA for nonvariceal upper GI bleeding; Infliximab retreatment results in remission in patients with Crohn’s disease; men who have sex with men twice as likely to be diagnosed with IBD and more.

Patients with poorly managed anxiety and pain during hospitalization had the highest risk for developing inflammatory bowel disease-related posttraumatic stress, according to research published in Inflammatory Bowel Diseases.

Two adalimumab biosimilars, adalimumab-adaz and adalimumab-fkjp, demonstrated safety and effectiveness in patients with Crohn’s disease and ulcerative colitis, according to a study in PLOS One.

In a Healio video exclusive, Freddy Caldera, DO, MS, urged providers to recommend the COVID-19 booster vaccine to all patients with inflammatory bowel disease.